PMO Interview with the Innovator Series: Volume 2

Peter Hirth, PhD
Video Categories: PMO Interview with the Innovator Series

The publishers of Personalized Medicine in Oncology (PMO) invite you to watch an interview with Peter Hirth, PhD, Chief Executive Officer of Plexxikon. In part one, Dr. Hirth discusses the use of biomarkers, segmenting the population of melanoma patients into subsets, and other aspects of personalized medicine.
October 16, 2015

Pembrolizumab vs. Ipilimumab

Dr. Sanjiv Agarwala discusses the pros and cons of using Pembrolizumab over anti-CTLA4 antibody therapy.

July 29, 2015

Introducing New Agents into the Standard of Care

Dr. S. Yosuf Zafar questions how to incorporate new agents into the standard of cancer care as many of these agents are both expensive and only useful for a small segment of patients.